PacBio narrows 2026 revenue guidance to $155M-$160M while targeting cash flow breakeven in 2028

PacBio narrowed its 2026 revenue guidance to $155M-$160M and targets cash flow breakeven in 2028.

PacBio narrowed its 2026 revenue guidance to $155M-$160M and targets cash flow breakeven in 2028.

话题：#PacBio 2026 revenue guidance and 2028 breakeven target

墨子AI